Novel Agonists of Adenosine Receptors in Animal Model of Acute Myocardial Infarction
Fabricio Beltrame,Bianca Nascimento-Carlos,Jaqueline da Silva,Rodolfo Maia,Tadeu Montagnoli,Eliezer Barreiro,Gisele Zapata-Sudo
DOI: https://doi.org/10.2147/dddt.s464712
IF: 4.3188
2024-11-20
Drug Design Development and Therapy
Abstract:Fabricio Beltrame, 1, 2 Bianca Nascimento-Carlos, 3 Jaqueline S da Silva, 1, 3 Rodolfo Couto Maia, 4 Tadeu Lima Montagnoli, 3, 4 Eliezer J Barreiro 3, 4 , † Gisele Zapata-Sudo 1– 4 1 Programa de Pós-Graduação em Medicina (Cardiologia), Faculdade de Medicina, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil; 2 Instituto do Coração Edson Saad, Faculdade de Medicina, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil; 3 Programa de Pós-Graduação em Farmacologia e Química Medicinal, Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil; 4 Programa de Pesquisa em Desenvolvimento de Fármacos, Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil †Professor Eliezer Barreiro passed away on April 8, 2024 Correspondence: Gisele Zapata-Sudo, Universidade Federal do Rio de Janeiro, Instituto do Coração Edson Saad, Faculdade de Medicina, Centro de Ciências da Saúde, Bloco J, Sala 11, Rio de Janeiro, RJ, 21941-902, Brasil, Tel/Fax +55-21-39386505, Email ; Background and Purpose: Current treatments for acute myocardial infarction (AMI) include pain relief and attempts to improve survival. This study investigated the effects of two new ligands of the adenosine receptor, LASSBio-1027 and LASSBio-1860, on cardiac function in an experimental model of AMI. Methods: AMI was induced in Wistar rats by ligating the anterior descending coronary arteries. Infarcted animals were treated orally with vehicle (DMSO), LASSBio-1027 (30 and 70 μmol/kg), or LASSBio-1860 (70 μmol/kg) for seven days. Hemodynamic parameters were observed using echocardiography, whereas inflammation and fibrosis were detected using histological analysis. Results: MI increased the filling pressure from 23.0 ± 1.6 and 14.0 ± 2.0 to 37.0 ± 3.7 and 33.2 ± 8.0, respectively indicating diastolic dysfunction. However, treatment with LASSBio-1027 (70 μmol/kg) and LASSBio-1860 (70 μmol/kg) reduced this parameter to 23.9 ± 5.4 and 17.1 ± 6.7. An impairment in ejection fraction from 57.1 ± 3.2 to 36.6 ± 2.0% was observed after MI, partially recovered to 47.0 ± 7.4% by LASSBio-1027 and fully restored to 61.8 ± 4.3% after 7 days of treatment with LASSBio-1860. After MI, collagen deposition in LV free wall was increased to 31.4 ± 11.0% and treatment with LASSBio-1027 reduced to 23.4 ± 6.0 and 19.7 ± 8.0% at 30 and 70 μmol/kg, respectively. Similarly, LASSBio-1860 reduced collagen levels to 63.1 ± 2.0%. Conclusion: Fibrosis and inflammatory components of MI reduced following treatment with agonist of adenosine receptor subtype A2A. Cardiac remodeling induced by LASSBio-1027 and LASSBio-1860 may be responsible for the improvement in cardiac function in AMI through the activation of A2A adenosine receptors. Keywords: cardiac remodeling, inflammation, myocardial infarction, adenosine receptors AMI remains the leading cause of death among patients with cardiovascular disease. AMI results from sustained ischemia and consists of three phases: inflammatory, proliferative, and reparative. Each phase is intricately regulated by various cell types and cytokine levels. 1,2 Notably, cytokines such as tumor necrosis factor-alpha (TNF-α), interleukin (IL)-1β, and IL-6 not only promote cell recruitment, extracellular matrix (ECM) degradation, and fibroblast activation within the necrotic core, but also adversely affect healthy myocardial regions, contributing to cardiac dysfunction, ventricular remodeling, and heart failure. 3 Recent evidence highlights the pivotal role of cardiac fibroblasts in fibrosis, responding to microenvironmental stimuli and directly acting on the ECM in cardiac tissue. 4 During the healing process, this appears as upregulation in fibrosis-associated genes, promoting ECM synthesis and remodeling. 5 Consequently, persistent stimuli that disrupt the ventricular structure ultimately result in impaired systolic and diastolic functions. 6 Current guidelines for AMI treatment do not provide pharmacological strategies to control inflammation. 7,8 Therefore, it is important to identify new therapeutic targets that regulate the inflammatory response during the early phase of AMI, thereby improving cardiac performance. One potential target is the adenosine system, which promotes different physiological or pathological responses in several tissues, including the immune, cardiovascular, and nervous systems. 9 Adenosine activates four subtypes of membrane G protein-coupled receptors, named adenosine receptors (AR): A 1 -AR, A 2A - -Abstract Truncated-
pharmacology & pharmacy,chemistry, medicinal